Chan E, et al. - The goal of this paper was to analyze the safety and efficacy of mocetinostat (a Class I/IV HDAC inhibitor) in combination with gemcitabine in patients with solid tumors, including pancreatic cancer. The finding shed light on the connection between mocetinostat three times per week (TIW) in combination with gemcitabine with prominent toxicities in patients with advanced pancreatic cancer. The level of clinical activity of this treatment combination did not appear to be high enough to merit additional evaluation in this scenario.